Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference
Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN
Company to Host Analyst and Investor Conference Call on
Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Alector plans to host a conference call to review the AL001 Phase 2 results on
Alector will also present two posters related to its AL002 Alzheimer’s disease (AD) program. The first poster will include the results of the AL002 Phase 1 study in healthy volunteers and the second poster will highlight the study design of the ongoing INVOKE-2 trial in people with early AD.
Oral Presentation for AL001 Phase 2 Data
Presentation Title: Six Months Interim Analysis of the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (#54593)
Presenter: Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector
Session Date and Time:
Poster Presentations for AL002
Poster presentations will be available for on-demand viewing beginning on
Poster Title: INVOKE-2 – A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer’s Disease (#54615)
Presenting Author: Robert Paul, M.D., Ph.D., Chief Medical Officer, Alector
Poster Title: A Phase 1 Study of AL002 in
Alector AL001 Conference Call Information
Alector management will host a conference call at
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
VP, Communications and Investor Relations
Source: Alector, Inc.